Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology

被引：62

作者：

Shibata, H. ^{[1
]}

Kato, S. ^{[2
,10
]}

Sekine, I. ^{[3
]}

Abe, K. ^{[4
]}

Araki, N. ^{[5
]}

Iguchi, H. ^{[6
]}

Izumi, T. ^{[7
]}

Inaba, Y. ^{[8
]}

Osaka, I. ^{[9
]}

Kato, S. ^{[2
,10
]}

Kawai, A. ^{[11
]}

Kinuya, S. ^{[12
]}

Kodaira, M. ^{[13
]}

Kobayashi, E. ^{[11
]}

Kobayashi, T. ^{[14
]}

Sato, J. ^{[15
]}

Shinohara, N. ^{[16
]}

Takahashi, S. ^{[17
]}

Takamatsu, Y. ^{[18
]}

Takayama, K. ^{[19
,20
]}

Tateishi, U. ^{[21
]}

Nagakura, H. ^{[22
]}

Hosaka, M. ^{[23
]}

Morioka, H. ^{[24
]}

Moriya, T. ^{[25
]}

Yuasa, T. ^{[26
]}

Yurikusa, T. ^{[27
]}

Yomiya, K. ^{[28
]}

Yoshida, M. ^{[29
]}

机构：

[1] Akita Univ, Grad Sch Med, Dept Clin Oncol, Akita, Japan

[2] Juntendo Univ, Dept Clin Oncol, Tokyo, Japan

[3] Univ Tsukuba, Dept Clin Oncol, Tsukuba, Ibaraki, Japan

[4] Chiba Prefectural Univ Hlth Sci, Dept Rehabil, Chiba, Japan

[5] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Orthoped Surg, Osaka, Japan

[6] Natl Hosp Org Shikoku Canc Ctr, Dept Gastroenterol, Matsuyama, Ehime, Japan

[7] Tochigi Canc Ctr, Div Hematol, Utsunomiya, Tochigi, Japan

[8] Aichi Canc Ctr Hosp, Dept Diagnost & Intervent Radiol, Nagoya, Aichi, Japan

[9] Shizuoka Canc Ctr, Div Palliat Med, Sunto Gun, Japan

[10] Iwate Cent Prefectural Hosp, Dept Canc Chemotherapy, Morioka, Iwate, Japan

[11] Natl Canc Ctr, Div Musculoskeletal Oncol, Tokyo, Japan

[12] Kanazawa Univ Hosp, Dept Nucl Med, Kanazawa, Ishikawa, Japan

[13] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan

[14] Ishikawa Prefectural Cent Hosp, Dept Diagnost & Intervent Radiol, Kanazawa, Ishikawa, Japan

[15] Iwate Med Univ, Sch Pharm, Dept Clin Pharmaceut, Morioka, Iwate, Japan

[16] Hokkaido Univ, Grad Sch Med, Dept Renal & Genitourinary Surg, Sapporo, Hokkaido, Japan

[17] Canc Inst Hosp Japanese Fdn Canc Res, Dept Med Oncol, Tokyo, Japan

[18] Fukuoka Univ Hosp, Div Med Oncol Hematol & Infect Dis, Fukuoka, Japan

[19] Seirei Christopher Univ, Hamamatsu, Shizuoka, Japan

[20] Kyushu Univ, Grad Sch Med Sci, Res Inst Dis Chest, Fukuoka, Japan

[21] Tokyo Med & Dent Univ, Dept Diagnost Radiol & Nucl Med, Tokyo, Japan

[22] KKR Sapporo Med Ctr, Dept Radiol, Sapporo, Hokkaido, Japan

[23] Tohoku Uni, Grad Sch Med, Dept Orthopaed Surg, Sendai, Miyagi, Japan

[24] Keio Univ, Sch Med, Dept Orthopaed Surg, Tokyo, Japan

[25] Kawasaki Med Sch, Department Pathol 2, Kurashiki, Okayama, Japan

[26] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Urol, Tokyo, Japan

[27] Shizuoka Canc Ctr, Div Dent & Oral Surg, Sunto Gun, Japan

[28] Saitama Canc Ctr, Depnt Palliat Care, Kitaadachi Gun, Japan

[29] Int Univ Hlth & Welf, Chemotherapy Res Inst, Dept Hemodialysis & Surg, Ichikawa, Japan

来源：

ESMO OPEN | 2016年 / 1卷 / 02期

关键词：

D O I：

10.1136/esmoopen-2016-000037

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Diagnosis and treatment of bone metastasis requires various types of measures, specialists and caregivers. To provide better diagnosis and treatment, a multidisciplinary team approach is required. The members of this multidisciplinary team include doctors of primary cancers, radiologists, pathologists, orthopaedists, radiotherapists, clinical oncologists, palliative caregivers, rehabilitation doctors, dentists, nurses, pharmacists, physical therapists, occupational therapists, medical social workers, etc. Medical evidence was extracted from published articles describing meta-analyses or randomised controlled trials concerning patients with bone metastases mainly from 2003 to 2013, and a guideline was developed according to the Medical Information Network Distribution Service Handbook for Clinical Practice Guideline Development 2014. Multidisciplinary team meetings are helpful in diagnosis and treatment. Clinical benefits such as physical or psychological palliation obtained using the multidisciplinary team approaches are apparent. We established a guideline describing each specialty field, to improve understanding of the different fields among the specialists, who can further provide appropriate treatment, and to improve patients' outcomes.

引用

页数：11

共 141 条

[1] Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis [J].

Aguiar Bujanda, D. ;

Bohn Sarmiento, U. ;

Cabrera Suarez, M. A. ;

Aguiar Morales, J. .

ANNALS OF ONCOLOGY, 2007, 18 (03) :556-560

[2]

Allemani C, 1979, Lancet, Patent No. 25676887

[3]

[Anonymous], J CLIN ONCOL

[4]

[Anonymous], 2015, NATYRE, V385, P977

[5]

[Anonymous], 2012, LANCET, V379, P39

[6]

[Anonymous], 2009, J ORAL MAXILLOFICAL, V67, P2

[7]

[Anonymous], 2004, CANCER, V100, P2613

[8]

[Anonymous], ACUTE LOW

[9] Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study [J].

Atahan, Lale ;

Yildiz, Ferah ;

Cengiz, Mustafa ;

Kaplan, Bunyamin ;

Ozkan, Metin ;

Yazici, Gozde ;

Gundog, Mete ;

Haydaroglu, Ayfer ;

Korcum, Aylin F. ;

Sengoz, Meric ;

Dincer, Maktav ;

Akmansu, Muege ;

Engin, Kayihan ;

Hayran, Mutlu .

SUPPORTIVE CARE IN CANCER, 2010, 18 (06) :691-698

[10] Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].

Bamias, A ;

Kastritis, E ;

Bamia, C ;

Moulopoulos, LA ;

Melakopoulos, L ;

Bozas, G ;

Koutsoukou, V ;

Gika, D ;

Anagnostopoulos, A ;

Papadimitriou, C ;

Terpos, E ;

Dimopoulos, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587

← 1 2 3 4 5 6 7 8 9 10 →